Cansu Koç
Research Subjects
Cansu Koç has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Firdevs Baş
Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
2 shared publications - Güven Toksoy
Department of Medical Genetics, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
2 shared publications - Melek Yildiz
Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
2 shared publications Ad Kardelen
İstanbul University, İstanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, İstanbul, Turkey
1 shared publicationAsli Derya Kardelen Al
1 shared publication- Aslı Derya Kardelen
Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Elsevier in SSRN Electronic Journal
Long-term growth and growth hormone treatment in CSGALNACT1-related skeletal dysplasia: three siblings with a novel homozygous nonsense variant
Biallelic CSGALNACT1 variants impair chondroitin sulfate biosynthesis and cause a rare skeletal dysplasia. Longitudinal growth data and experience with recombinant human growth hormone (rhGH) remain limited. We describe three siblings of consanguineous parents with a homozygous nonsense variant, c.429T>G, p.(Tyr143*). All three had prenatal limb shortening, disproportionate short stature, joint hypermobility, skin hyperextensibility, and mild skeletal abnormalities. Exome sequencing identified the variant in the index patient, and Sanger sequencing confirmed segregation in the family. The siblings received rhGH for 8.1-12.2 years, with treatment initiated before molecular diagnosis under different endocrine indications. Height standard deviation scores increased by 0.61, 1.87, and 1.39 from treatment initiation to the last assessment, respectively. First-year gains were limited in two siblings. At the last assessment, the eldest sibling had discontinued treatment, whereas the other two remained on rhGH. No slipped capital femoral epiphysis or progression of scoliosis was documented. Bone age was concordant with chronological age at the latest assessment in all three; infant hand-wrist radiographs were unavailable. These observations extend the longitudinal clinical description of CSGALNACT1-related skeletal dysplasia but do not establish disease-specific rhGH efficacy or general safety. Molecular diagnosis can inform reassessment of treatment indications. Normal bone age later in childhood should not preclude genetic evaluation when disproportionate short stature and joint hypermobility suggest an underlying skeletal disorder.
- 8 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLong-term growth and growth hormone treatment in CSGALNACT1-related skeletal dysplasia: three siblings with a novel homozygous nonsense variant
Biallelic CSGALNACT1 variants impair chondroitin sulfate biosynthesis and cause a rare skeletal dysplasia. Longitudinal growth data and experience with recombinant human growth hormone (rhGH) remain limited. We describe three siblings of consanguineous parents with a homozygous nonsense variant, c.429T>G, p.(Tyr143*). All three had prenatal limb shortening, disproportionate short stature, joint hypermobility, skin hyperextensibility, and mild skeletal abnormalities. Exome sequencing identified the variant in the index patient, and Sanger sequencing confirmed segregation in the family. The siblings received rhGH for 8.1-12.2 years, with treatment initiated before molecular diagnosis under different endocrine indications. Height standard deviation scores increased by 0.61, 1.87, and 1.39 from treatment initiation to the last assessment, respectively. First-year gains were limited in two siblings. At the last assessment, the eldest sibling had discontinued treatment, whereas the other two remained on rhGH. No slipped capital femoral epiphysis or progression of scoliosis was documented. Bone age was concordant with chronological age at the latest assessment in all three; infant hand-wrist radiographs were unavailable. These observations extend the longitudinal clinical description of CSGALNACT1-related skeletal dysplasia but do not establish disease-specific rhGH efficacy or general safety. Molecular diagnosis can inform reassessment of treatment indications. Normal bone age later in childhood should not preclude genetic evaluation when disproportionate short stature and joint hypermobility suggest an underlying skeletal disorder.
- 30 September 2026
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 30 (10) , 489
Evaluating dental developmental abnormalities in osteogenesis imperfecta: associations with timing and cumulative exposure to intravenous pamidronate- a pilot study
- 30 September 2026
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 30 (10) , 489
Evaluating dental developmental abnormalities in osteogenesis imperfecta: associations with timing and cumulative exposure to intravenous pamidronate- a pilot study
- Open Access
- 10 July 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (1) , 105-112
Young Turkish Adults Show a Continuing Positive Secular Change of Height But an Alarming Increase of Overweight in Males: Pilot Study for the Initiation of Updated Growth Charts
Young Turkish Adults Show a Continuing Positive Secular Change of Height But an Alarming Increase of Overweight in Males: Pilot Study for the Initiation of Updated Growth Charts - Journal of Clinical Research in Pediatric Endocrinology
- 10 July 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (1) , 105-112
Open AccessYoung Turkish Adults Show a Continuing Positive Secular Change of Height But an Alarming Increase of Overweight in Males: Pilot Study for the Initiation of Updated Growth Charts
Young Turkish Adults Show a Continuing Positive Secular Change of Height But an Alarming Increase of Overweight in Males: Pilot Study for the Initiation of Updated Growth Charts - Journal of Clinical Research in Pediatric Endocrinology
- Open Access
- 8 January 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e220524
The effect of anastrozole therapy on final height and sex hormone levels in pubertal boys receiving growth hormone therapy
Objective: This research aimed to evaluate retrospectively the effect of anastrozole on height gain and sex hormone levels in pubertal boys receiving growth hormone (GH). Materials and methods: Pubertal boys who received both GH and anastrozole (GH+A) were one-to-one matched with boys who received only GH (GH-Only) for chronological and bone age, pubertal stage and height before the GH initiation, treatment duration and midparental height. Anthropometric measurements throughout treatment and adult heights were compared between the groups. Sex hormone [...] ABSTRACT Objective: This research aimed to evaluate retrospectively the effect of anastrozole on height gain and sex hormone levels in pubertal boys receiving growth hormone (GH). Materials and methods: Pubertal boys who received both GH and anastrozole (GH+A) were one-to-one matched with boys who received only GH (GH-Only) for chronological and bone age, pubertal stage and height before the GH initiation, treatment duration and midparental height. Anthropometric measurements throughout treatment and adult heights were compared between the groups. Sex hormone
- 8 January 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e220524
Open AccessThe effect of anastrozole therapy on final height and sex hormone levels in pubertal boys receiving growth hormone therapy
Objective: This research aimed to evaluate retrospectively the effect of anastrozole on height gain and sex hormone levels in pubertal boys receiving growth hormone (GH). Materials and methods: Pubertal boys who received both GH and anastrozole (GH+A) were one-to-one matched with boys who received only GH (GH-Only) for chronological and bone age, pubertal stage and height before the GH initiation, treatment duration and midparental height. Anthropometric measurements throughout treatment and adult heights were compared between the groups. Sex hormone [...] ABSTRACT Objective: This research aimed to evaluate retrospectively the effect of anastrozole on height gain and sex hormone levels in pubertal boys receiving growth hormone (GH). Materials and methods: Pubertal boys who received both GH and anastrozole (GH+A) were one-to-one matched with boys who received only GH (GH-Only) for chronological and bone age, pubertal stage and height before the GH initiation, treatment duration and midparental height. Anthropometric measurements throughout treatment and adult heights were compared between the groups. Sex hormone